Viewpoint: CalRx biosimilar insulin: CA's initiative to enter the insulin market

California's pending entry into the insulin market is a response to decades of consistent and steep price increases for insulin products.

Full story

#1

Physicians are in short supply. They are costly. Is the APP the answer to the CMO's workforce and budget challenges? ...

Amid the hype and promise, a growing tension is becoming clear: the reality of what AI can deliver versus what it can't. ...